Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Review 2017: Animal Pharm's highlights of the year

There have been many changes across the animal health sector in 2017, both in terms of new legislation and industry consolidation.

In the attached PDF below, Animal Pharm subscribers can read about the milestone moments of the year, including the trends currently shaping the animal health industry.

The report covers the impact of changes to regulations governing the use of antibiotics, the scramble for next-generation alternative veterinary medicines, the latest destinations for investment in animal health, the new vision for Boehringer Ingelheim Animal Health and the possibilities for Elanco's future.

Download Animal Pharm's highlights of 2017 here

The report samples Animal Pharm's most read interviews and analysis articles from 2017. Animal Pharm will return in the new year with more exclusive analysis of last year's themes in innovation, investment, M&A, product approvals and much more.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AP013427

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel